ALK and non-small cell lung carcinoma: Over the past decade, treatment modalities for advanced NSCLC have evolved from traditional chemotherapies such as cytotoxic platinum-based drugs towards more effective regimens that are targeted towards specific molecular subtypes, including those that display epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) fusion oncogenes [7,8].